Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,149.50    10.50 (0.92%)
Bid:
1,149.00
Ask:
1,150.00
Spread: 1.00 (0.087%)
Market Cap: £9.76b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Transaction in Own Shares

2 Aug 2017 17:22

RNS Number : 9546M
Smith & Nephew Plc
02 August 2017
Β 

2 August 2017

Smith & Nephew plc (the "Company")

Β 

Transaction in Own Shares

Β 

The Company today purchased 309,247 of its Ordinary Shares of US 20Β’ each through Merrill Lynch International, in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 6 April 2017. These shares were issued in connection with employee share schemes in Quarter 2 2017 and have been purchased as part of a programme to reduce the Company's share capital, in order to keep it broadly constant, as announced on 1 August 2017. Details of the relevant purchase transactions are set out below:

Β 

Description of Shares:

Smith & Nephew Ordinary Shares of US 20Β’ each

Number of Shares repurchased:

309,247

Average price paid per Share:

1,319.9881p

Highest price paid per Share:

1,325.0000p

Lowest price paid per Share:

1,317.0000p

Date of transaction:

2 August 2017

Broker:

Merrill Lynch International

Β 

The Company intends to hold these shares in Treasury.

Β 

Following the purchase of these shares, the Company holds 15,898,225 of its shares in Treasury. The Company's issued share capital, with one voting right per share consists of 875,095,052 Ordinary Shares of US20Β’ each (excluding treasury shares). This is the figure which should be used by shareholders as the denominator when determining whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

These purchases were made by Merrill Lynch International on behalf of the Company and a full breakdown of the individual trades is attached to this announcement.http://www.rns-pdf.londonstockexchange.com/rns/9546M_-2017-8-2.pdf

Β 

This announcement is made in accordance with the requirements of LR 12.4.6.

Β 

Vickie Reuben

Deputy Company Secretary

Smith & Nephew plc

Tel: 01923 477320

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
POSSSUFMEFWSEFA
Date   Source Headline
5th Jun 202612:12 pmRNSTransaction in Own Shares
4th Jun 20264:05 pmRNSDirector/PDMR Shareholding
3rd Jun 202611:21 amRNSDirector/PDMR Shareholding
3rd Jun 202610:35 amRNSAdmission to Trading
1st Jun 20263:10 pmRNSTotal Voting Rights
29th May 202610:37 amRNSTransaction in Own Shares
27th May 20269:31 amRNSPre Stabilisation Notice
22nd May 20261:32 pmRNSAdmission to Trading
22nd May 20269:58 amRNSTransaction in Own Shares
20th May 202611:25 amRNSDirector/PDMR Shareholding
19th May 20268:53 amRNSHolding(s) in Company
15th May 202612:28 pmRNSTransaction in Own Shares Replacement
15th May 202611:41 amRNSTransaction in Own Shares
14th May 20269:25 amRNSHolding(s) in Company
12th May 20264:03 pmRNSSterling Amount of Dividend
8th May 20267:00 amRNSShare Buyback Programme
6th May 20262:25 pmRNSResult of AGM
6th May 20267:00 amRNSSmith+Nephew First Quarter 2026 Trading Update
1st May 20261:10 pmRNSTotal Voting Rights
27th Apr 20267:00 amRNSExpert surgeons insights event for investors
22nd Apr 20268:46 amRNSNotice of Results
16th Apr 202611:12 amRNSDirector/PDMR Shareholding
15th Apr 20263:46 pmRNSDirector Declaration
14th Apr 20262:59 pmRNSReplacement: Annual Financial Report & AGM Notice
1st Apr 202612:23 pmRNSTotal Voting Rights
24th Mar 20264:16 pmRNSDirector/PDMR Shareholding
24th Mar 20268:45 amRNSHolding(s) in Company
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
10th Mar 20262:30 pmRNS-RSmith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
5th Mar 20267:30 amRNSDirector Declaration
2nd Mar 20261:36 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSFinal Results
5th Feb 202611:56 amRNSNotice of Results
2nd Feb 20264:00 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Feb 20263:05 pmRNSTotal Voting Rights
23rd Jan 20262:00 pmRNSDirector/PDMR Shareholding
21st Jan 20264:11 pmRNSCompletion of Acquisition
12th Jan 20264:30 pmRNSAcquisition of Integrity Orthopaedics
2nd Jan 202610:07 amRNSTotal Voting Rights
8th Dec 20257:00 amRNSNew Strategy and 2028 Financial Targets
1st Dec 20254:10 pmRNSTotal Voting Rights
19th Nov 202510:00 amRNSDirector/PDMR Shareholding
18th Nov 202510:18 amRNSHolding(s) in Company
12th Nov 20259:24 amRNSDirector/PDMR Shareholding
11th Nov 20254:40 pmRNSHolding(s) in Company
10th Nov 20251:46 pmRNSDirector/PDMR Shareholding
7th Nov 20259:38 amRNSDirector/PDMR Shareholding
7th Nov 20259:35 amRNSDirector/PDMR Shareholding
6th Nov 20257:01 amRNSDirectorate change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.